Listen to insights on haematology data, as discussed by experts in the field
Listen to Prof. Andrew Davies discuss the benefit of using Gazyvaro over Rituximab in 1L FL patients.
Listen to Prof. Andrew Davies discuss his experience with Gazyvaro, and the endpoints from the GALLIUM trial.
Listen to Dr William Townsend discuss PET & MRD from the GALLIUM trial, and the relevance of having minimal residual disease, from Haem Live 2019.
Listen to Dr William Townsend and Dr Wendy Osborne discuss the GALLIUM 4-year follow-up results, and the clinical relevance of endpoints.
Listen to Prof. Andrew Davies discuss FAQs about GALLIUM, including the study design and efficacy vs safety.
A discussion including Prof Russell Patmore, Dr Wendy Osborne and
Dr Graham Collins exploring the findings from the retrospective sub-analysis of the GALLIUM study in patients with FLIPI scores ≥2.
1L, first-line; CLL, chronic lymphocytic leukaemia; FAQs, frequently asked questions; FL, follicular lymphoma; FLIPI, Follicular Lymphoma International Prognostic Index; MRD, minimal residual disease; PET, positron emission tomography.
Date of preparation: March 2020